Adobe Systems Inc vs Alcon AG — how do they compare? Adobe Systems Inc trades at $260.9 (market cap $104.82B), while Alcon AG trades at $72.61 (market cap $36.44B). The key difference: Adobe Systems Inc is far larger — about 2.9× Alcon AG's market cap, and Alcon AG pays a 0.48% dividend while Adobe Systems Inc pays none. Which is the better fit depends on your goals.
| ADBE | ALC | |
|---|---|---|
Market Cap | $104.82B | $36.44B |
Volume | 5,187,646 | — |
Sector | Technology | Health |
52-Week High | $367.46 | $90.12 |
52-Week Low | $193.41 | $62.02 |
Enterprise Value | $106.26B | $40.28B |
Dividend Yield | — | 0.48% |
Signals from Pluang's Aura AI — not financial advice
Adobe (ADBE) trades at $272.96, up 2.92% with strong technical momentum above key support at $270. The company demonstrates robust fundamentals with 2025 revenue of $23.77B and net income of $7.13B, maintaining exceptional profitability with 89.4% gross margins. Recent earnings beats and accelerating revenue growth contrast with mixed sentiment amid AI competition concerns and CEO transition uncertainty.
ADBE presents a compelling value proposition trading below analyst consensus targets with strong cash flow generation, though faces headwinds from AI disruption fears and sector volatility. The stock's current valuation at 15.62 P/E offers potential upside if execution continues, but requires monitoring of competitive threats and leadership stability.
No Aura AI signal available yet.
Trailing returns across standard periods
Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.
Read more on ADBE →Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →